NEW: the results of the ADVANCE-ON trial were just released at the ESC Congress in Barcelona (1st September 2014) and at the EASD Congress in Vienna (19th September 2014) and demonstrated significant benefits in survival, 10 years after the initiation of a perindopril-indapamide (Preterax) strategy, and substantial reductions in end stage renal disease, 10 years after initiation of a gliclazide MR (Diamicron MR)-based intensive glucose control strategy, in patients with type 2 diabetes.
These results are reported in a paper published online in the New England Journal of Medicine (ePUB ahead of print) on the 19th September 2014, and available at